Bristol-Myers Squibb Company (NYSE:BMY) : The consensus price target for Bristol-Myers Squibb Company (NYSE:BMY) is $73.86 for the short term with a standard deviation of $13.47. The most optimist securities analyst among the 14 who monitor the stock believes that the stock can reach $100, however, the pessimist price target for the company is $48.
Shares of Bristol-Myers Squibb Company rose by 1.79% in the last five trading days and 2.88% for the last 4 weeks. Bristol-Myers Squibb Company is up 13.91% in the last 3-month period. Year-to-Date the stock performance stands at 8.13%. Also, Equity Analysts at the Brokerage Firm, Jefferies, maintains their rating on the shares of Bristol-Myers Squibb Company (NYSE:BMY). Jefferies has a Hold rating on the shares. As per the latest research report, the brokerage house raises the price target to $78 per share from a prior target of $76. The rating by the firm was issued on June 14, 2016.
Bristol-Myers Squibb Company (NYSE:BMY) : 7 brokerage houses believe that Bristol-Myers Squibb Company (NYSE:BMY) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 7 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Bristol-Myers Squibb Company (NYSE:BMY). Zacks Investment Research suggests a Strong Buy with a rank of 1. 2 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 17 Wall Street Analysts endorse the stock as a Buy with a rating of 2.32.
Bristol-Myers Squibb Company (NYSE:BMY): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $73.10 and $72.71 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $73.75. The buying momentum continued till the end and the stock did not give up its gains. It closed at $73.55, notching a gain of 0.75% for the day. The total traded volume was 5,763,885 . The stock had closed at $73.00 on the previous day.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (SVP, Public Affairs & IR) of Bristol Myers Squibb Co, Elicker John E had sold 11,820 shares worth of $859,196 in a transaction dated June 14, 2016. In this transaction, 11,820 shares were sold at $72.69 per share.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.